An in silico approach to the identification of diagnostic and prognostic markers in low-grade gliomas

Low-grade gliomas (LGG) are central nervous system Grade I tumors, and as they progress they are becoming one of the deadliest brain tumors. There is still great need for timely and accurate diagnosis and prognosis of LGG. Herein, we aimed to identify diagnostic and prognostic biomarkers associated with LGG, by employing diverse computational approaches. For this purpose, differential gene expression analysis on high-throughput transcriptomics data of LGG versus corresponding healthy brain tissue, derived from TCGA and GTEx, respectively, was performed. Weighted gene co-expression network analysis of the detected differentially expressed genes was carried out in order to identify modules of co-expressed genes significantly correlated with LGG clinical traits. The genes comprising these modules were further used to construct gene co-expression and protein-protein interaction networks. Based on the network analyses, we derived a consensus of eighteen hub genes, namely, CD74, CD86, CDC25A, CYBB, HLA-DMA, ITGB2, KIF11, KIFC1, LAPTM5, LMNB1, MKI67, NCKAP1L, NUSAP1, SLC7A7, TBXAS1, TOP2A, TYROBP, and WDFY4. All detected hub genes were up-regulated in LGG, and were also associated with unfavorable prognosis in LGG patients. The findings of this study could be applicable in the clinical setting for diagnosing and monitoring LGG.

[1]  Xiaofeng Yin,et al.  Identification of novel prognostic targets in glioblastoma using bioinformatics analysis , 2022, Biomedical engineering online.

[2]  M. Sanson,et al.  Expression and Prognostic Value of CD80 and CD86 in the Tumor Microenvironment of Newly Diagnosed Glioblastoma , 2022, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[3]  Qianrong Huang,et al.  Screening and Identification of Key Biomarkers in Lower Grade Glioma via Bioinformatical Analysis , 2022, Applied bionics and biomechanics.

[4]  Chenjie Gu,et al.  Metabolic Signature-Based Subtypes May Pave Novel Ways for Low-Grade Glioma Prognosis and Therapy , 2021, Frontiers in Cell and Developmental Biology.

[5]  Xuan Wang,et al.  Aberrant nuclear lamina contributes to the malignancy of human gliomas. , 2021, Journal of genetics and genomics = Yi chuan xue bao.

[6]  Q. Cheng,et al.  CD74 Correlated With Malignancies and Immune Microenvironment in Gliomas , 2021, Frontiers in Molecular Biosciences.

[7]  W. Wang,et al.  ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas , 2021, Cancer Immunology, Immunotherapy.

[8]  B. Mroczko,et al.  Molecular and Circulating Biomarkers of Brain Tumors , 2021, International journal of molecular sciences.

[9]  W. Zhang,et al.  GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA , 2021, Nucleic Acids Res..

[10]  Yan Wang,et al.  Screening and identification of LMNB1 and DLGAP5, two key biomarkers in gliomas , 2021, Bioscience reports.

[11]  Zhaotao Wang,et al.  Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma , 2021, BMC Cancer.

[12]  Ning Liu,et al.  Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma , 2021, Frontiers in Oncology.

[13]  Wentao Liu,et al.  The Solute Carrier Family 7 Genes Are Potential Diagnostic and Prognostic Biomarkers in Lower Grade Glioma , 2021 .

[14]  A. Bhatia,et al.  IDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions , 2021, Current Oncology Reports.

[15]  Gang Zhang,et al.  Upregulation of KIF11 in TP53 Mutant Glioma Promotes Tumor Stemness and Drug Resistance , 2021, Cellular and Molecular Neurobiology.

[16]  Xinjun Wang,et al.  Kinesin Family Member C1 Increases Temozolomide Resistance of Glioblastoma Through Promoting DNA Damage Repair , 2021, Cell transplantation.

[17]  Jiaxuan Zou,et al.  A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma , 2021, Technology in cancer research & treatment.

[18]  James C. Wright,et al.  GENCODE 2021 , 2020, Nucleic Acids Res..

[19]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[20]  B. Kamińska,et al.  The novel, recurrent mutation in the TOP2A gene results in the enhanced topoisomerase activity and transcription deregulation in glioblastoma , 2020, bioRxiv.

[21]  B. Kamińska,et al.  TOP2A substitution enhances topoisomerase activity and causes transcriptional dysfunction in glioblastoma patients , 2020 .

[22]  M. Knoll,et al.  LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance , 2020, Frontiers in Oncology.

[23]  Xu Ren,et al.  RNAAgeCalc: A multi-tissue transcriptional age calculator , 2020, bioRxiv.

[24]  Z. Wang,et al.  Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients , 2020, bioRxiv.

[25]  Giovanni Parmigiani,et al.  ComBat-seq: batch effect adjustment for RNA-seq count data , 2020, bioRxiv.

[26]  J. Sarkaria,et al.  Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma , 2019, Scientific Reports.

[27]  K. Xiao,et al.  Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas , 2019, Front. Genet..

[28]  V. Martins,et al.  Aberrant expression of RSK1 characterizes high‐grade gliomas with immune infiltration , 2019, Molecular oncology.

[29]  M. Kukar,et al.  Diagnosing brain tumours by routine blood tests using machine learning , 2019, Scientific Reports.

[30]  James M. Cameron,et al.  Development of high-throughput ATR-FTIR technology for rapid triage of brain cancer , 2019, Nature Communications.

[31]  Jennifer S. Yu,et al.  Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal? , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[32]  J. Buckner,et al.  Controversies in the Therapy of Low-Grade Gliomas , 2019, Current Treatment Options in Oncology.

[33]  L. Bello,et al.  Mapping in Low-Grade Glioma Surgery: Low- and High-Frequency Stimulation. , 2019, Neurosurgery clinics of North America.

[34]  M. Diamond,et al.  WDFY4 is required for cross-presentation in response to viral and tumor antigens , 2018, Science.

[35]  E. Mazzon,et al.  Overexpression of macrophage migration inhibitory factor and functionally-related genes, D-DT, CD74, CD44, CXCR2 and CXCR4, in glioblastoma , 2018, Oncology letters.

[36]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[37]  Bin Wang,et al.  Over-expression of TOP2A as a prognostic biomarker in patients with glioma. , 2018, International journal of clinical and experimental pathology.

[38]  Zhitong Bing,et al.  Integrated mRNAseq and microRNAseq data analysis for grade III gliomas , 2017, Molecular medicine reports.

[39]  Haibo Xu,et al.  Gene expression meta-analysis in diffuse low-grade glioma and the corresponding histological subtypes , 2017, Scientific Reports.

[40]  D. Solomon,et al.  Characterization of gliomas: from morphology to molecules , 2017, Virchows Archiv.

[41]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[42]  Jeffrey T Leek,et al.  Reproducible RNA-seq analysis using recount2 , 2017, Nature Biotechnology.

[43]  P. Delgado-López,et al.  Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies , 2017, Clinical and Translational Oncology.

[44]  D. Schiff.  Low-grade Gliomas , 2017, Continuum.

[45]  Anindya Dutta,et al.  Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis , 2016, PLoS medicine.

[46]  M. Weller,et al.  The Role of Molecular Diagnostics in the Management of Patients with Gliomas , 2016, Current Treatment Options in Oncology.

[47]  H. Colman,et al.  Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future , 2016, Current Treatment Options in Oncology.

[48]  Jorge Cadima,et al.  Principal component analysis: a review and recent developments , 2016, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[49]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[50]  S. Rosenfeld,et al.  The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma , 2015, Science Translational Medicine.

[51]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[52]  J. Raizer,et al.  Current Understanding and Treatment of Gliomas , 2015 .

[53]  M. Berger,et al.  Survival and low-grade glioma: the emergence of genetic information. , 2015, Neurosurgical focus.

[54]  Chung-Yen Lin,et al.  cytoHubba: identifying hub objects and sub-networks from complex interactome , 2014, BMC Systems Biology.

[55]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[56]  C. Chapman,et al.  Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. , 2014, Cancer research.

[57]  B. Nahed,et al.  Low-grade gliomas. , 2014, The oncologist.

[58]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[59]  Q. Lan,et al.  Genetic variants in SLC7A7 are associated with risk of glioma in a Chinese population , 2013, Experimental biology and medicine.

[60]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[61]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[62]  Sandrine Dudoit,et al.  GC-Content Normalization for RNA-Seq Data , 2011, BMC Bioinformatics.

[63]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[64]  G. Cochrane,et al.  The International Nucleotide Sequence Database Collaboration , 2011, Nucleic Acids Res..

[65]  Hideaki Sugawara,et al.  The Sequence Read Archive , 2010, Nucleic Acids Res..

[66]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[67]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[68]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[69]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..